City
Epaper

Exports of SII vaccine blocked till March-April

By IANS | Published: January 18, 2021 12:44 PM

New Delhi, Jan 18 Exports of the Oxford-AstraZeneca vaccine by the Serum Institute of India are currently blocked ...

Open in App

New Delhi, Jan 18 Exports of the Oxford-AstraZeneca vaccine by the Serum Institute of India are currently blocked until March or April, as India (along with China) look set to take the lead in driving the region's distribution efforts in the months ahead, according to Moodys Analytics.

It said that India's advancement towards inoculations is a crucial development for the region.

India has approved two vaccines approved for emergency use last week one developed by Oxford University and AstraZeneca, the other domestically developed by Bharat Biotech and the Indian Council of Medical Research.

Starting January 16, the Indian government's plan is to inoculate nearly 300 million high-priority people including health workers, the elderly, and those with higher comorbidities by August, Moody's Analytics has said.

"This is an important development. As India is the second most-impacted country in the world, after the US, the need for local immunization is paramount to contain the significant socioeconomic costs, and the country's success in advancing on this front will eventually soften the severity of the pandemic within the region," it said.

Plus, as the largest producer of vaccines in the world, with 60 per cent of the global share, India is well-positioned to use its existing manufacturing capabilities to contribute to mass vaccine production and distribution needs for other countries in addition to meeting its domestic requirements, it added.

Although exports of the Oxford-AstraZeneca vaccine by the Serum Institute of India are currently blocked until March or April, India (along with China) look set to take the lead in driving the region's distribution efforts in the months ahead, Moody's Analytics said.

Mixed reports on the effectiveness of (China's) Sinovac vaccine, for instance, have set back vaccination efforts in countries considering its use as part of their inoculation drive. So while the short-term risks from intensifying domestic outbreaks have increased and will dampen the March quarter recovery in Japan, Malaysia and South Korea, the potential upsides to regional recovery in the second half of 2021 have not appreciably shied our outlook, the report said.

( With inputs from IANS )

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: Moody's AnalyticsindiaNew DelhiSerum Institute Of IndiaThe new delhi municipal councilDelhi south-westSerum institute of india pvt. ltdIndiUk-indiaRepublic of indiaSerum india
Open in App

Related Stories

PoliticsHome Minister Amit Shah Warns of 'Babri Lock' at Ram Temple if I.N.D.I.A Bloc Comes to Power

InternationalCBI Arrests 4 for Trafficking Indians Into Russia-Ukraine Conflict Zone (See Tweet)

National‘British Raj-Like Conditions’ Prevailing in India Under PM Modi Govt, Says Priyanka Gandhi

BusinessIndia Witnessed a 59% Surge in Ghost Shopping Malls in 2023: 16 Retail Centers Shut Across Top Cities

NationalIndia Weather Update: IMD Warns of Heatwave Across Multiple Regions on May 6

Health Realted Stories

HealthKnow what is West Nile fever spreading in Kerala

HealthStopped manufacturing, supply of additional Covishield doses, disclosed all side effects: Serum Institute

HealthAstraZeneca recalls Covid vax: Risk-benefit currently against further use, say experts

HealthICMR-NIN revises dietary guidelines to check nutrient deficiencies, obesity, diabetes

HealthGates Foundation-backed Axmed raises funds to help poor countries access critical medicines